Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 81

Results For "MD"

2310 News Found

Sun Pharma launches Unloxcyt for advanced cutaneous squamous cell carcinoma treatment
News | January 16, 2026

Sun Pharma launches Unloxcyt for advanced cutaneous squamous cell carcinoma treatment

UNLOXCYT is an evolution in checkpoint inhibition and is now available for the treatment of adults in the U.S. with mCSCC or laCSCC who are not candidates for curative surgery or curative radiation


Avantium and Packamama join forces to revolutionise wine packaging with plant-based polymer
Packaging | January 16, 2026

Avantium and Packamama join forces to revolutionise wine packaging with plant-based polymer

The partnership aims to fuse Avantium’s breakthrough materials with Packamama’s expertise in low-emission, innovative wine bottles


Bayer acquires Attralus’ cardiac amyloidosis imaging agents
News | January 16, 2026

Bayer acquires Attralus’ cardiac amyloidosis imaging agents

The deal to acquire AT-01 (124-Iodine-evuzamitide) and AT-05 (PAR-Peptide + technetium-99m) underscores Bayer’s commitment to expanding in molecular imaging and advancing precision cardiology


CARsgen and Dispatch Bio launch groundbreaking CAR T collaboration in China
Clinical Trials | January 15, 2026

CARsgen and Dispatch Bio launch groundbreaking CAR T collaboration in China

CARsgen is working to transform outcomes for patients with solid tumors by advancing the potential of CAR T technologies


Teva’s AJOVY gains spotlight as first preventive migraine treatment for kids
R&D | January 15, 2026

Teva’s AJOVY gains spotlight as first preventive migraine treatment for kids

The findings, from the SPACE study, paved the way for FDA approval of AJOVY for pediatric patients aged 6-17 years weighing 45 kilograms


Bristol Myers Squibb reports positive Phase 3 results for Camzyos in adolescents with oHCM
Clinical Trials | January 14, 2026

Bristol Myers Squibb reports positive Phase 3 results for Camzyos in adolescents with oHCM

The study showed a statistically significant reduction in Valsalva left ventricular outflow tract (LVOT) gradient at Week 28 compared with placebo